Neumo­ra, Rayze­Bio ride on­to Nas­daq in IPO dou­ble­head­er, breath­ing life in­to fall list­ings

Two Phase III biotechs will join the Nas­daq Fri­day morn­ing, with ra­dio­phar­ma start­up Rayze­Bio and brain dis­ease drug de­vel­op­er Neumo­ra pric­ing their IPOs at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER